33.44 - 34.57
31.40 - 61.90
7.61M / 5.95M (Avg.)
-152.73 | -0.22
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
244.38%
Cash & equivalents growing 244.38% while PATH's declined -0.43%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
244.38%
Below half of PATH's -0.71%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
37.98%
Receivables growth above 1.5x PATH's 21.39%. Michael Burry would check for potential credit bubble or inflated top-line.
48.23%
Inventory growth above 1.5x PATH's 24.29%. Michael Burry might suspect a looming inventory glut. Check free cash flow impact.
12.54%
Other current assets growth < half of PATH's 64.86%. David Dodd sees a leaner approach to short-term items.
170.97%
≥ 1.5x PATH's 3.18%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
1.44%
0.75-0.9x PATH's 1.61%. Bill Ackman questions if competitor invests more heavily in future capacity.
No Data
No Data available this quarter, please select a different quarter.
14.90%
Less than half of PATH's -8.93%. David Dodd sees relatively fewer intangible expansions. Possibly more tangible-driven.
14.90%
Less than half of PATH's -3.49%. David Dodd sees fewer intangible expansions vs. competitor. Possibly safer balance sheet.
-27.28%
Below half of PATH's 49.27%. Michael Burry sees possible underinvestment in long-term assets. Verify capital constraints.
20.70%
Less than half of PATH's 55.24%. David Dodd sees fewer tax deferrals or losses, indicating stronger profitability vs. competitor.
17.45%
50-75% of PATH's 25.31%. Bruce Berkowitz notes relatively lower 'other assets' expansions.
7.91%
0.5-0.75x PATH's 13.31%. Martin Whitman wonders if there's insufficient reinvestment vs. competitor.
-100.00%
Higher Other Assets Growth compared to PATH's zero value, indicating worse performance.
86.77%
≥ 1.5x PATH's 4.25%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
29.38%
Less than half of PATH's -51.90%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
11.04%
0.5-0.75x PATH's 17.48%. Martin Whitman sees weaker advanced billings vs. competitor.
52.46%
Less than half of PATH's -8.43%. David Dodd sees fewer expansions in other current obligations.
18.95%
1.25-1.5x PATH's 12.89%. Martin Whitman is wary of bigger short-term burdens.
No Data
No Data available this quarter, please select a different quarter.
6.74%
Below half PATH's 16.64%. Michael Burry suspects a serious gap in multi-year pipeline.
-100.00%
Similar yoy changes to PATH's -99.50%. Walter Schloss sees parallel tax deferral patterns.
113.30%
Less than half of PATH's -35.01%. David Dodd notes more conservative expansions in non-current obligations.
-79.68%
Less than half of PATH's 5.16%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-60.58%
Less than half of PATH's 11.34%. David Dodd sees far fewer liability expansions relative to competitor.
1350.00%
Higher Common Stock (Book Value) Growth compared to PATH's zero value, indicating worse performance.
-37.83%
≥ 1.5x PATH's -4.40%. David Dodd sees higher yoy retained profits than competitor.
-308.70%
Less than half of PATH's 184.49%. David Dodd sees fewer intangible or market-driven swings than competitor.
100.00%
Higher Other Stockholders' Equity Items Growth compared to PATH's zero value, indicating worse performance.
257.16%
≥ 1.5x PATH's 2.04%. David Dodd sees stronger capital base growth than competitor.
86.77%
≥ 1.5x PATH's 4.25%. David Dodd sees faster overall balance sheet growth than competitor.
-27.28%
Below half PATH's 0.74%. Michael Burry suspects major underinvestment or forced divestment.
-2.72%
Similar yoy changes to PATH's -2.58%. Walter Schloss notes parallel total debt strategies.
-555.11%
Less than half of PATH's 0.37%. David Dodd sees better deleveraging or stronger cash buildup than competitor.
